Ligand Pharmaceuticals Incorporated Common Stock Earnings Dividend

Ligand Pharmaceuticals Incorporated Common Stock’s revenue jumped 33.73% since last year same period to $63.69Mn in the Q2 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated 23.14% jump in its revenue since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s net profit jumped 900.78% since last year same period to $48.51Mn in the Q2 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated 463.49% jump in its net profits since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s net profit margin jumped 648.35% since last year same period to 76.16% in the Q2 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated 395.17% jump in its net profit margins since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.34 - a -25.56% fall from last quarter’s estimates.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at 1.34.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) jumped 825% since last year same period to 2.22 in the Q2 2026. This indicates that the Ligand Pharmaceuticals Incorporated Common Stock has generated 825% annual rate of jump in its earning per share (EPS) in the last 4 quarters.